Rallybio Deal History & Licensing Activity
Rallybio is a life sciences. Over the past three years, Rallybio has been involved in 4 licensing and acquisition transactions, with a primary focus on Other (6 deals).
Deals (12mo)
3
Active Trials
0
Top Modality
Other
Focus Area
Mega Deals
Rallybio Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Rallybio in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| rare disease program | Avenzo | Other | Unknown | collaboration | Jun 2026 |
| rare disease / immunology program | Avenzo Therapeutics | Other | Unknown | collaboration | Jun 2026 |
| rare disease program | Avenzo | Other | Unknown | collaboration | Jun 2026 |
Rallybio Pipeline Focus
Therapeutic areas and modalities where Rallybio is most active based on deal history and clinical trial data.
Rallybio Strategic Signals
Key indicators of Rallybio's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
See How Your Asset Matches Rallybio's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Mega Deals assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
ADC Benchmarks
Upfront, milestone, and royalty benchmarks for adc deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Rallybio Licensing & Deal Activity
Rallybio is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 4 deals over the past three years, Rallybio ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Rallybio include Mega Deals (8 deals and trials). In terms of modality, Rallybio has shown particular interest in other, adc.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Rallybio and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Rallybio's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.